2024-511858-44-00招募中2 期
Cell therapy for Inclusion Body Myositis (IBM) by muscle injection of autologous uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF): a phase I trial
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 38
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Investigateur coordonnateur
Scientific
Assistance Publique Hopitaux De Paris
研究点 (4)
Loading locations...
相似试验
招募中
1 期
Cell Therapy for IBM by Muscle Injection of ADSVFInclusion Body MyositisNCT05032131Assistance Publique - Hôpitaux de Paris32
已完成
早期 1 期
Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body MyositisInclusion Body MyositisNCT00802815Washington University School of Medicine20
已完成
不适用
Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative CellsInclusion Body MyositisNCT04975841University of Kansas Medical Center9
招募中
2 期
A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse2024-518275-64-00Instytut Hematologii I Transfuzjologii340
Unknown
不适用
Pharmacoepidemiologic General Research Extension: PGRx-sIBM StudySporadic Inclusion Body MyositisNCT02735447La-ser Europe Limited190